Abstract
The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are a class of drug used to lower low-density lipoprotein (LDL) levels. However, in recent years, statins have been shown to possess a pleiotropic effect beyond its cholesterol lowering ability, including attenuating the effect of ischaemia reperfusion injury. This review considers the biomolecular processes that may lead to this beneficial effect.
Keywords: Ischaemia reperfusion injury, statins, 3-hydroxy-3-methyl-glutaryl-CoA, reductase inhibitors, low-density lipoprotein, inflammatory re-sponse syndrome, multi organs dysfunction syn-drome, tissue hypoxia, hypoxanthine, xanthine oxidase, reactive oxygen species, nuclear factor B, activator protein-1, nitric oxide, endothelial dysfunction, inter-leukin (IL)-1, tumour necrosis factor alpha, platelet-activating factor, sialyl Lewis X, thrombin, cytokines, vascular endothelial cadherin, angioplasty, cholesterol biosynthesis, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, cytochrome P450, coronary heart disease, rhabdo-myolysis, endothelial NO synthase, inducible NO synthase, neuronal NO synthase, Pro-Inflammatory Cytokines, PAF receptor, endothelin-1, monocyte chemoattractant protein-1, thrombomodulin, cytokine transcription, C-reactive protein, Leukocytes-Endothelial Interaction, decay-accelerating factor, protein kinase C, NADPH-oxidase, ROS reduction
Current Vascular Pharmacology
Title: Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review
Volume: 8 Issue: 6
Author(s): M. N.A. Abdul Rahman and Ian C. Chetter
Affiliation:
Keywords: Ischaemia reperfusion injury, statins, 3-hydroxy-3-methyl-glutaryl-CoA, reductase inhibitors, low-density lipoprotein, inflammatory re-sponse syndrome, multi organs dysfunction syn-drome, tissue hypoxia, hypoxanthine, xanthine oxidase, reactive oxygen species, nuclear factor B, activator protein-1, nitric oxide, endothelial dysfunction, inter-leukin (IL)-1, tumour necrosis factor alpha, platelet-activating factor, sialyl Lewis X, thrombin, cytokines, vascular endothelial cadherin, angioplasty, cholesterol biosynthesis, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, cytochrome P450, coronary heart disease, rhabdo-myolysis, endothelial NO synthase, inducible NO synthase, neuronal NO synthase, Pro-Inflammatory Cytokines, PAF receptor, endothelin-1, monocyte chemoattractant protein-1, thrombomodulin, cytokine transcription, C-reactive protein, Leukocytes-Endothelial Interaction, decay-accelerating factor, protein kinase C, NADPH-oxidase, ROS reduction
Abstract: The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are a class of drug used to lower low-density lipoprotein (LDL) levels. However, in recent years, statins have been shown to possess a pleiotropic effect beyond its cholesterol lowering ability, including attenuating the effect of ischaemia reperfusion injury. This review considers the biomolecular processes that may lead to this beneficial effect.
Export Options
About this article
Cite this article as:
N.A. Abdul Rahman M. and C. Chetter Ian, Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563780
DOI https://dx.doi.org/10.2174/157016110793563780 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Wound Healing Activity of Hydro-alcoholic Extract of Cinnamomum nitidum Blume (Lauraceae) in Wistar Albino Rats
Current Traditional Medicine Subject Index to Volume 1
Vascular Disease Prevention (Discontinued) Persistent Pulmonary Hypertension of the Newborn: Therapeutical Approach
Mini-Reviews in Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Overview of Medicinally Important Diterpenoids Derived from Plastids
Mini-Reviews in Medicinal Chemistry Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Antioxidative Properties of Flavonoids
Current Organic Chemistry Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design Hydrogen Sulfide in Diabetic Complications: Focus on Molecular Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology Hyperglycemia Induced Changes in Liver: In vivo and In vitro Studies
Current Diabetes Reviews Subject Index to Volume 2
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry